Canagliflozin is an oral medication that helps control blood sugar levels by helping kidneys get rid of glucose from your bloodstream. Besides, the mediation also aids in reducing cardiovascular and renal events in patients with type-2 diabetes. The objective of this study is to investigate the renal, cardiovascular, and safety outcomes of canagliflozin.
This randomized study included a total of 4,401 participants with an eGFR of 30 to <90 ml/min per 1.73 m2. The participants were randomly assigned to either canagliflozin 100 mg or placebo. The primary outcome of the study was renal efficacy, cardiovascular efficacy, and safety outcomes analyzed by Cox proportional hazards regression.
Of 4,041 participants, 1313 (30%) has eGFR <45, 1279 (29%) had 45 to <60, and 1809 (41%) had 60 to <90 ml/min. The positive renal and cardiovascular outcomes of canagliflozin were consistent among all eGFR subgroups. The findings also suggested that subgroups with lower eGFRs, who were at greater risk, experienced larger absolute renal benefits. No treatment-related adverse events or deaths were reported in any of the subgroups.
The research concluded that canagliflozin effectively and safely attenuated the risk of adverse renal and cardiovascular events across all eGFR subgroups, ranging from 30 to <90 ml/min.